Transactions
10
Insider / BIOGEN INC.
Keeney Adam
Head of Corporate Development at BIOGEN INC.
- Company
- BIOGEN INC.
- Ticker
- BIIB
- First filing on record
- February 10, 2026
- Latest trade on record
- May 1, 2026
- SEC filings
- EDGAR ↗
Keeney Adam, Head of Corporate Development at BIOGEN INC., has disclosed 10 transactions in BIIB since February 10, 2026: 0 purchases (0 open-market buys) and 3 sales, worth about $404K at the reported prices. The latest was filed May 5, 2026, 4 days after the trade.
Open-market buys
0
Sales
3
Avg. disclosure lag
4.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Keeney Adam made no purchases and 3 sales worth $404K, plus 7 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Keeney Adam has traded 1 stock on record; the largest by dollars is BIIB.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 6 | 12,038 | — |
| F | Shares withheld for tax | 3 | 2,038 | $404K |
| A | Grant or award | 1 | 8,025 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 10 | 0 | 3 · $404K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BIIB | Option / conversion M | May 1, 2026 | May 5, 2026 | 4d | 939 | — | — | derivative | Form 4 ↗ | |
| BIIB | Sell F | May 1, 2026 | May 5, 2026 | 4d | 455 | $187 | $85K | Form 4 ↗ | ||
| BIIB | Option / conversion M | May 1, 2026 | May 5, 2026 | 4d | 939 | — | — | Form 4 ↗ | ||
| BIIB | Other A | February 13, 2026 | February 17, 2026 | 4d | 8,025 | — | — | derivative | Form 4 ↗ | |
| BIIB | Option / conversion M | February 6, 2026 | February 10, 2026 | 4d | 3,278 | — | — | derivative | Form 4 ↗ | |
| BIIB | Option / conversion M | February 6, 2026 | February 10, 2026 | 4d | 1,802 | — | — | derivative | Form 4 ↗ | |
| BIIB | Sell F | February 6, 2026 | February 10, 2026 | 4d | 994 | $201 | $200K | Form 4 ↗ | ||
| BIIB | Option / conversion M | February 6, 2026 | February 10, 2026 | 4d | 3,278 | — | — | Form 4 ↗ | ||
| BIIB | Sell F | February 6, 2026 | February 10, 2026 | 4d | 589 | $201 | $118K | Form 4 ↗ | ||
| BIIB | Option / conversion M | February 6, 2026 | February 10, 2026 | 4d | 1,802 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 5, 2026 | Form 4 | 0000875045-26-000046 | 3 | published | EDGAR ↗ |
| February 17, 2026 | Form 4 | 0000875045-26-000031 | 1 | published | EDGAR ↗ |
| February 10, 2026 | Form 4 | 0000875045-26-000020 | 6 | published | EDGAR ↗ |
Other insiders at BIOGEN INC.
- Godbout Sean Chief Accounting Officer 20 rows
- Singhal Priya Head of Development 12 rows
- Murphy Nicole Head of Pharm Ops and Tech 11 rows
- ALEXANDER SUSAN H EVP Chief Legal Officer 10 rows
- Gregory Ginger EVP, Human Resources 10 rows
- Grogan Jane Head of Research 10 rows
- Izzar Rachid Head of Global Product Strat. 10 rows
- Kramer Robin Chief Financial Officer 10 rows
- Viehbacher Christopher President and CEO 10 rows
- Patolawala Monish D Director 5 rows
Everyone on file, with contracts and lobbying under the company's name: BIOGEN INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 10 | February 10, 2026 | May 5, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.